Fimecs Inc., of Kanagawa, Japan, raised ¥250 million (US$2.3 million) in funding by third-party allocation of shares underwritten by Tokyo-based Cosmo Bio Co. Ltd. and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan. The company plans to use the proceeds to fund research and development of its protein degradation therapeutics for the treatment of cancer. In other news, Fimecs licensed immuno-oncology compounds, including E3 ligase binders and pseudokinase targeting binders, from Takeda Pharmaceutical.